Resverlogix Corp. fell 12.5% on Thursday, November 5, 2026, on 216,400 shares, 8.0 times its average daily volume. No headline about RVX came out that day or the day before in the news feeds we follow, so the move may come from news we don't track, the sector or trading alone.
Resverlogix Corp. (RVX:TSX) closed at $0.075 on November 6, 2026, up 7.14% on the day. The stock trades 50.0% below its 52-week high of $0.150 and 25.0% above its 52-week low of $0.060. Over the past year, it lost 25.0%. Resverlogix Corp. is part of the Life Sciences sector (Biotechnology).
In 252 trading sessions since November 6, 2025, RVX closed higher on 37 days (15%). Its best day was September 25, 2026 (+22.22%) and its worst was November 5, 2026 (-12.50%). The stock moved 10% or more in a single session 20 times. It opened at least 5% above the previous day's high 17 times.
Resverlogix is a late stage clinical biotechnology company developing apabetalone, a first-in-class and safe small molecule, that is a selective BET inhibitor with potentially important benefits for patients with high-risk CVD, diabetes, and CKD.
Find more stocks like RVX with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.